<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347346</url>
  </required_header>
  <id_info>
    <org_study_id>GTG003.08</org_study_id>
    <secondary_id>2009-011152-22</secondary_id>
    <nct_id>NCT01347346</nct_id>
  </id_info>
  <brief_title>Gene Therapy for WAS</brief_title>
  <official_title>Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genethon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hôpital Necker-Enfants Malades</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genethon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II study to evaluate the safety and efficacy of Hematopoietic Stem Cell
      genetherapy for the Wiskott-Aldrich Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is an ex vivo gene therapy trial. The investigational product corresponds
      to autologous CD34+ cells transduced with a lentiviral vector harboring the human WASP gene.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 9, 2017</completion_date>
  <primary_completion_date type="Actual">January 13, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in the eczema status</measure>
    <time_frame>2 years</time_frame>
    <description>Improvement in eczema status as compared with the baseline status at study entry on clinical evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in the frequency and severity of infection episodes</measure>
    <time_frame>2 years</time_frame>
    <description>Reduction in the frequency and severity of infection episodes as compared with the baseline status and the patient's historical data collected over the 2 years prior to study entry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in the frequency and severity of bruising and bleeding episodes</measure>
    <time_frame>2 years</time_frame>
    <description>Reduction in the frequency and severity of bruising and bleeding episodes as compared with the baseline status and the patient's historical data collected over the 2 years prior to study entry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in the frequency and severity of autoimmune disorders</measure>
    <time_frame>2 years</time_frame>
    <description>Reduction in the frequency and severity of autoimmune disorders as compared with the baseline status at study entry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in the number of disease related days of hospitalization</measure>
    <time_frame>2 years</time_frame>
    <description>Reduction in the number of disease related days of hospitalization as compared with the patient's historical data collected over the 2 years prior to study entry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence and type of adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Occurrence and type of adverse events reported during the course of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in medical conditions</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of weight, vital signs, ECG and laboratory exams during the course of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of lentivirus gene transfer into Hematopoietic Stem Cells</measure>
    <time_frame>3, 6, 12, 24 months / 6, 12, 18, 24 months</time_frame>
    <description>Detection of replication competent lentivirus (RCL) and lentivirus integration sites analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of microthrombocytopenia</measure>
    <time_frame>3, 6, 12, 24 months</time_frame>
    <description>Improvement of microthrombocytopenia as compared with the baseline evaluation at study entry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in the number and volume of platelets transfusions</measure>
    <time_frame>2 years</time_frame>
    <description>Decrease in the number and volume of platelets transfusions as compared with patient's historical data collected over the 2 years prior to study entry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of sustained engraftment of WASP-expressing transduced cells</measure>
    <time_frame>6 weeks, 1, 3, 6, 9, 12, 18 &amp; 24 months</time_frame>
    <description>Quantification of vector copy numbers and detection of vector-derived WASP expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reconstitution of humoral and cell mediated immunity</measure>
    <time_frame>9, 12, 18 &amp; 24 months</time_frame>
    <description>Reconstitution of humoral and cell mediated immunity as compared with the baseline evaluation at study entry</description>
  </secondary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>Wiskott-Aldrich Syndrome</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene</intervention_name>
    <description>transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males of all ages

          -  severe WAS (clinical score 3-5) or absence of WAS protein in peripheral blood
             mononuclear cells determined by Western blotting and flow cytometry

          -  molecular confirmation by WAS gene DNA sequencing

          -  lack of HLA-genotypically identical bone marrow after 3 month search

          -  lack of a 10/10 or 9/10 antigen HLA-matched unrelated donor after 3 month search

          -  lack of a HLA-matched cord blood after 3 month search

          -  parental, guardian, patient signed informed consent/assent

          -  willing to return for follow-up

          -  only for patients who have received previous allogenic hematopoietic stem cell
             transplant:

          -  failed allogenic hematopoietic stem cell transplant

          -  contraindication to repeat transplantation

        Exclusion Criteria:

          -  patient with HLA-genotypically identical bone marrow

          -  patient with 10/10 or 9/10 antigen HLA-matched unrelated donor or with HLA-matched
             cord blood

          -  contraindication to leukapheresis

          -  contraindication to bone marrow harvest

          -  contraindication to administration of conditioning medication

          -  HIV positive patient
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Wiskott-Aldrich Syndrome</keyword>
  <keyword>Primary immune deficiency</keyword>
  <keyword>ex vivo gene therapy</keyword>
  <keyword>hematopoietic stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

